WO2018101443A1 - 医療用皮膚外用剤 - Google Patents
医療用皮膚外用剤 Download PDFInfo
- Publication number
- WO2018101443A1 WO2018101443A1 PCT/JP2017/043180 JP2017043180W WO2018101443A1 WO 2018101443 A1 WO2018101443 A1 WO 2018101443A1 JP 2017043180 W JP2017043180 W JP 2017043180W WO 2018101443 A1 WO2018101443 A1 WO 2018101443A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alcohol
- external preparation
- acid
- medical
- fatty acid
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Definitions
- the present invention relates to 1-cyclopropyl-8-methyl-7- [5-methyl-6- (methylamino) -3-pyridyl] -4-oxo-1,4-dihydro-3-quinolinecarboxylic acid (hereinafter referred to as The present invention relates to a skin external preparation for medical use, which contains “Compound A”) and / or a pharmaceutically acceptable salt thereof as an active ingredient.
- An object of the present invention is to provide a medical skin external preparation mainly containing Compound A as an active ingredient and suitable for the treatment of superficial skin infections, particularly superficial skin infections associated with blisters and erosions. There is.
- the present inventors have solved the above-mentioned problem by adding alcohol and / or fatty acid in a medical skin external preparation containing Compound A and / or a pharmaceutically acceptable salt thereof as an active ingredient.
- the present inventors have found that this can be done and have completed the present invention.
- the medical skin external preparation which has high stability can be provided by controlling the peroxide value of the alcohol and / or fatty acid to add to 120 meq / kg or less.
- Examples of the present invention include the following. (1) A medical skin external preparation containing compound A and / or a pharmaceutically acceptable salt thereof as an active ingredient and containing an alcohol and / or fatty acid having 12 or more carbon atoms (hereinafter referred to as “the medical skin of the present invention”). "External preparation”). (2) The medical skin external preparation of the present invention as described in 1 above, which is further excellent in stability of the active ingredient. (3) The external skin preparation for medical use according to 1 or 2 above, wherein the content of the decomposition product of the active ingredient is 0.5% or less of the active ingredient.
- the decomposition product of the active ingredient is 1-cyclopropyl-3-hydroxy-8-methyl-7- (5-methyl-6- (methylamino) pyridin-3-yl) quinolin-4 (1H) -one 4.
- the medical skin external preparation of the present invention according to any one of 1 to 3 above, wherein (5) The external skin preparation for medical use according to any one of (1) to (4) above, wherein the peroxide value of alcohol and / or fatty acid is 120 meq / kg or less. (6) The external skin preparation for medical use according to any one of (1) to (4) above, wherein the peroxide value of alcohol and / or fatty acid is 40 meq / kg or less.
- the external skin preparation for medical use according to any one of 1 to 6 above which is lauryl alcohol, hexyl decanol, isostearyl alcohol, oleyl alcohol, octyldodecanol, oleic acid, isostearic acid and / or stearic acid.
- FIG. 1 shows the transdermal absorbability of Compound A according to the medical external skin preparation of the present invention.
- the vertical axis represents the cumulative skin permeation amount (ng / cm 2 ) of Compound A, and the horizontal axis represents time.
- ⁇ represents cream 13
- ⁇ represents cream 14
- ⁇ represents cream 15
- ⁇ represents cream 16
- ⁇ represents cream 17.
- Compound A is classified as a quinolone-based synthetic antibacterial compound, and inhibits DNA gyrase and topoisomerase IV involved in bacterial DNA replication to inhibit Gram-positive bacteria, Gram-negative bacteria, anaerobic bacteria, Chlamydia and drug-resistant Gram-positive compounds Has a broad antibacterial spectrum and strong antibacterial activity against bacteria.
- Examples of the pharmaceutically acceptable salt of Compound A include salts that are generally known in basic groups such as amino groups or acidic groups such as hydroxyl groups or carboxyl groups.
- Examples of the salt in the basic group include salts with mineral acids such as hydrochloric acid, hydrobromic acid and sulfuric acid; salts with organic carboxylic acids such as tartaric acid, formic acid, fumaric acid, maleic acid, malic acid and citric acid; And salts with sulfonic acids such as methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, mesitylenesulfonic acid and naphthalenesulfonic acid.
- mineral acids such as hydrochloric acid, hydrobromic acid and sulfuric acid
- salts with organic carboxylic acids such as tartaric acid, formic acid, fumaric acid, maleic acid, malic acid and citric acid
- salts with sulfonic acids such as methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, mesitylenesulfonic acid and naphthalenes
- salts in the acidic group include salts with alkali metals such as sodium and potassium; salts with alkaline earth metals such as calcium and magnesium; ammonium salts; and amino acids such as lysine, arginine and ornithine, trimethylamine, triethylamine, Tributylamine, pyridine, N, N-dimethylaniline, N-methylpiperidine, N-methylmorpholine, diethylamine, dicyclohexylamine, procaine, dibenzylamine, N-benzyl- ⁇ -phenethylamine, 1-ephenamine and N, N′- Mention may be made of salts with nitrogen-containing organic bases such as dibenzylethylenediamine.
- the content of Compound A and / or a pharmaceutically acceptable salt thereof is not particularly limited as long as it exhibits a therapeutic effect.
- it is suitably within the range of 0.01 to 20% by weight in the preparation. In the range of 0.1 to 5% by weight.
- the optimum pH of the external preparation for medical use of the present invention is in the range of 9-13.
- the pH can be measured by a generally used method, and is not particularly limited. For example, after adding purified water to the preparation to dilute it about 10 times and warm, dissolve the preparation and mix, Centrifugation can be performed, and the lower layer portion can be collected to measure the pH.
- the alcohol and / or fatty acid according to the present invention has 12 or more carbon atoms, suitably 16 to 22 carbon atoms, and preferably 18 carbon atoms.
- the alcohol and / or fatty acid according to the present invention preferably has an unsaturated carbon bond and / or a branched chain. One or more of these can be used.
- C12 alcohol lauryl alcohol
- C13 alcohol tridecyl alcohol
- C14 alcohol myristyl alcohol
- C15 alcohol pentadecyl alcohol
- C16 alcohol cetanol (cetyl alcohol, Palmityl alcohol), hexyldecanol, palmitoleyl alcohol / 17-carbon alcohol: 1-heptadecanol / 18-carbon alcohol: stearyl alcohol, isostearyl alcohol, oleyl alcohol, elaidyl alcohol, linoleyl alcohol, elide reno Rail alcohol, linolenyl alcohol, elide linolenyl alcohol, ricinoleyl alcohol / C19 alcohol: Chimyl alcohol (glyceryl monocetylate) ), Nonadecyl alcohol / alcohol having 20 carbon atoms: octyldodecanol,
- the alcohol content in the external preparation for medical skin of the present invention is suitably in the range of 0.1 to 40% by weight, preferably in the range of 0.5 to 20% by weight, and in the range of 1 to 10% by weight.
- the inside is more preferable.
- the alcohol according to the present invention is suitably lauryl alcohol, hexyl decanol, isostearyl alcohol, oleyl alcohol or octyldodecanol, preferably isostearyl alcohol, oleyl alcohol or octyldodecanol, more preferably oleyl alcohol.
- the fatty acid according to the present invention is not particularly limited as long as it is pharmaceutically acceptable, and examples thereof include the following.
- C12 fatty acid lauric acid
- C14 fatty acid myristic acid
- C15 fatty acid pentadecyl acid
- C16 fatty acid palmitic acid
- C17 fatty acid margaric acid
- Fatty acid of number 18 stearic acid, isostearic acid, oleic acid, linoleic acid, vacenoic acid, linolenic acid, eleostearic acid.
- Fatty acid of carbon number 20 arachidic acid, 8,11-eicosadienoic acid, mead acid, arachidonic acid.
- C22 fatty acid behenic acid / C24 fatty acid: lignoceric acid, nervonic acid / C25 fatty acid: pentacosanoic acid / C26 fatty acid: serotic acid / C28 fatty acid: montanic acid / carbon number 30 fatty acids: melicic acid
- the content of fatty acid in the external preparation for medical skin of the present invention is suitably in the range of 0.1 to 40% by weight, preferably in the range of 0.5 to 20% by weight, and in the range of 1 to 10% by weight.
- the content is more preferably in the range of 1 to 5% by weight.
- the content of alcohol and fatty acid in the external preparation for medical use of the present invention is suitably in the range of 0.1 to 40% by weight, preferably in the range of 0.5 to 20% by weight, and 1 to 10% by weight. The range of is more preferable.
- fatty acid As the fatty acid according to the present invention, myristic acid, palmitic acid, stearic acid, oleic acid, isostearic acid and behenic acid are suitable, stearic acid, oleic acid and isostearic acid are preferred, and stearic acid is more preferred.
- the “medical skin external preparation” relating to the medical external skin preparation of the present invention means a preparation to be applied to human skin for medical use, and is not particularly limited as long as it is pharmaceutically acceptable.
- a preparation to be applied to human skin for medical use and is not particularly limited as long as it is pharmaceutically acceptable.
- an ointment for example, an ointment , Creams, lotions, gels or foams. Of these, ointments or creams are particularly preferred.
- An ointment is generally defined as a semi-solid preparation in which an active ingredient is dissolved or dispersed in a base and applied to the skin, and can be classified into an oily ointment and a water-soluble ointment.
- the oily ointment further comprises a dispersion type in which the active ingredient is a crystal and dispersed in the base, a droplet dispersion type in which the active ingredient is dissolved in the dissolving agent and dispersed in the base, and the active ingredient does not require a dissolving agent. It can be classified into a dissolved type dissolved in a base.
- Creams are generally defined as semi-solid preparations emulsified in oil-in-water or water-in-oil types that are applied to the skin.
- the base that can be used in the medical skin external preparation of the present invention is not particularly limited as long as it is pharmaceutically acceptable.
- examples thereof include oils and fats, waxes, hydrocarbons such as paraffin, and water. 1 type (s) or 2 or more types can be used.
- the fats and oils are not particularly limited, and examples thereof include vegetable oils or squalane, and these can be used alone or in combination.
- the wax is not particularly limited, and examples thereof include beeswax, honey beeswax, and lanolin, and one or more of these can be used.
- Paraffin is carbonized with chain length peaks (measured by gas chromatography) at C14-16, C18-22, C20-22, C20-26, C28-40 and C40-44, and chain lengths from C5 to C60 It is hydrogen, for example, white petrolatum, yellow petrolatum, white soft paraffin, liquid paraffin or light liquid paraffin, and these can be used alone or in combination.
- the decomposition product of Compound A is a compound represented by the following chemical formula (1-cyclopropyl-3-hydroxy-8-methyl-7- (5-methyl-6- (methylamino) pyridin-3-yl) Quinolin-4 (1H) -one).
- the peroxide value of alcohol and / or fatty acid added to the medical external preparation for medical use of the present invention should be 120 meq / kg or less. desirable.
- the degradation product is suppressed to 0.2% or less of the content of Compound A by setting the peroxide value of alcohol and / or fatty acid added to the medical external preparation for medical use of the present invention to 40 meq / kg or less. And the stability can be further improved.
- the content of the decomposition product can be measured by a method that can be generally used by those skilled in the art, and can be measured by, for example, high performance liquid chromatography.
- the peroxide value can be measured by a generally used method.
- the peroxide value is obtained by reacting a sample with potassium iodide and expressing the amount of liberated iodine molecules in the number of milliequivalents (kg) per kg of the sample.
- the amount of iodine molecules generated is determined by oxidation-reduction titration using sodium thiosulfate.
- Starch is used for titration and iodine starch reaction is used. Iodine molecules react with starch to give a blue-purple color, but when sodium thiosulfate is added, iodine molecules are reduced and released from the starch, and the color becomes lighter. The time when the color disappears is the end point of the titration.
- a pH adjusting agent can be added.
- a pH adjuster is not particularly limited as long as it is a compound having a buffering capacity.
- metal hydroxides such as potassium hydroxide, lithium hydroxide and sodium hydroxide; monoethanolamine, monoisopropanolamine, diethanolamine, diethanolamine Hydroxy lower alkylamines such as isopropanolamine, triethanolamine, triisopropanolamine and 2-amino-2-methyl-1,3-propanediol; sodium bicarbonate, sodium citrate, sodium lactate, disodium hydrogen phosphate, tartaric acid
- metal salts of weak acids such as sodium, and these can be used alone or in combination.
- the addition amount of the pH adjusting agent is not particularly limited as long as the pH of the external preparation for medical use of the present invention can be adjusted to 9 to 13, but it is suitably in the range of 0.1 to 20% by weight. It is preferably in the range of 1 to 10% by weight, more preferably in the range of 0.1 to 5% by weight.
- a preservative can be further added to the medical external preparation for medical use of the present invention.
- the preservative is not particularly limited, and examples thereof include sodium edetate hydrate, tetrasodium edetate, sodium dehydroacetate, sorbic acid, potassium sorbate, phenoxyethanol, sodium benzoate, methyl parahydroxybenzoate, ethyl paraoxybenzoate. Propyl paraoxybenzoate, thymol, benzalkonium chloride, or dry sodium sulfite, and one or more of them can be used.
- a stabilizer (including an antioxidant) can be further added to the medical skin external preparation of the present invention.
- the stabilizer include, but are not limited to, ascorbic acid and derivatives thereof, sodium edetate, sodium thiosulfate, sodium sulfite, sodium pyrosulfite, sodium nitrite, or dibutylhydroxytoluene. Two or more kinds can be used.
- An ultraviolet absorber can be further added to the medical external preparation for medical use of the present invention.
- the ultraviolet absorber include, but are not limited to, for example, paraaminobenzoic acid, phenyl salicylate, isopropyl paramethoxycinnamate, octyl paramethoxycinnamate, or 2,4-dihydroxybenzophenone. Two or more kinds can be used.
- a solubilizer (solvent) as an active ingredient can be added to the medical external preparation for medical use of the present invention.
- the active ingredient solubilizer is not particularly limited.
- a wetting agent can be further added to the medical external preparation for medical use of the present invention.
- the wetting agent is not particularly limited, and examples thereof include 1,3-butylene glycol, glycerin, propylene glycol, or dipropylene glycol, and one or more of these can be used.
- An emulsifier can be further added to the medical external preparation for medical use of the present invention.
- the emulsifier is not particularly limited, but is cetyltrimethylammonium chloride, lauryldimethylbenzylammonium chloride, tetrabutylammonium chloride, dioctadecyldimethylammonium chloride, sodium alkylbenzene sulfonate, sodium dodecyl sulfate, coconut alcohol ethoxy sulfate, ⁇ -olefin sulfone.
- Acid sodium emulsified cetostearyl alcohol, polyoxyethylene alkyl ether, polyoxyethylene alkylphenol ether, polyoxyethylene hydrogenated castor oil, polyoxyl stearate, glycerin fatty acid ester, diglycerin fatty acid ester, N-alkyl-N, N-dimethylammonium
- examples include betaine or imidazoline type amphoteric surfactants. It is possible to use two or more.
- An emulsion stabilizer can be further added to the medical skin external preparation of the present invention.
- the emulsification stabilizer is not particularly limited, and examples thereof include L-arginine, glycine or sodium N-acyl-L-glutamate, and one or more of these can be used.
- a thickener (including a gelling agent) can be further added to the medical external skin preparation of the present invention.
- the thickener is not particularly limited, and examples include sodium alginate, gelatin, carboxyvinyl polymer, sodium polyacrylate, methylcellulose, glycerin monooleate, hydroxypropylcellulose, hydroxypropylmethylcellulose, hydroxyethylcellulose or xanthan gum. One or more of these can be used.
- a foaming agent can be further added to the medical external preparation for medical use of the present invention.
- the foaming agent is not particularly limited, but for example, polyoxyethylene sorbitan monostearate, glyceryl stearate, polyoxyethylene hydrogenated castor oil, polyethylene glycol monostearate, sucrose laurate, polyoxyethylene stearyl ether, Examples thereof include sodium laurate, arginine stearate, and sodium lauryl sulfate, and these can be used alone or in combination.
- the medical skin external preparation of the present invention may further contain additives generally used for other skin external preparations.
- the medical skin external preparation of the present invention can be widely used for the purpose of treating and / or preventing dermatological infections due to the antibacterial action of the active ingredient.
- the dermatological region infection that can use the medical external preparation for medical use of the present invention is not particularly limited as long as it is a disease in which bacterial infection is one of the etiologies, for example, simple skin soft tissue infection, complex skin soft tissue Mention can be made of acne with infection or purulent inflammation.
- Examples of simple skin and soft tissue infections include superficial skin infections and deep skin infections. Of these, superficial skin infections are particularly preferred.
- Superficial skin infections can be divided into attachment-related infections and non-attachment-related infections.
- Examples of the appendage-related infection include folliculitis, vellus or purulent periperitis.
- Examples of non-attachment device-related infections include infectious impetigo.
- complex skin and soft tissue infections can also be divided into appendage-related infections and non-appendage-related infections.
- appendage-related infections include, for example, tsutsu, scabies, and so on.
- non-annex-related infections include cellulitis, erysipelas, lymphangitis, or lymphadenitis.
- Chronic pyoderma Complex skin soft tissue infections can be divided into chronic pyoderma and secondary skin infections.
- chronic pyoderma include infectious masses and suppurative dysentery.
- secondary skin infections include secondary infections such as skin ulcers.
- Examples of acne with purulent inflammation include acne vulgaris, newborn acne, or confluent acne.
- the skin preparation for medical use of the present invention is less irritating to the skin and is particularly useful for diseases and symptoms associated with blisters and erosions among these dermatological infections.
- diseases and symptoms associated with blisters and erosions among these dermatological infections include, but are not limited to, contagious impetigo.
- the method for producing the external preparation for medical use of the present invention is not particularly limited, and can be produced by a method that can be generally used by those skilled in the art.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
主な治療法としては、外用抗菌剤や経口抗菌剤が用いられ、ナジフロキサシンやミノサイクリン、ロキシスロマイシンなどの抗菌剤が用いられてきた。最近では、新たな医薬品として、化合物Aを有効成分として含有する製剤が上市されている(特許文献1、特許文献2)。
さらに、添加するアルコール及び/又は脂肪酸の過酸化物価を120meq/kg以下にコントロールすることで、高い安定性を有する医療用皮膚外用剤を提供できることを見出した。
(1)化合物A及び/又はその医薬上許容される塩を有効成分として含有し、炭素数が12以上のアルコール及び/又は脂肪酸を含有する医療用皮膚外用剤(以下、「本発明医療用皮膚外用剤」という)。
(2)さらに、有効成分の安定性に優れた上記1に記載の本発明医療用皮膚外用剤。
(3)当該有効成分の分解物の含有量が当該有効成分の0.5%以下であることを特徴とする、上記1又は2に記載の本発明医療用皮膚外用剤。
(4)当該有効成分の分解物が1-シクロプロピル-3-ヒドロキシ-8-メチル-7-(5-メチル-6-(メチルアミノ)ピリジン-3-イル)キノリン-4(1H)-オンであることを特徴とする、上記1~3のいずれかに記載の本発明医療用皮膚外用剤。
(5)アルコール及び/又は脂肪酸の過酸化物価が120meq/kg以下であることを特徴とする、上記1~4のいずれかに記載の本発明医療用皮膚外用剤。
(6)アルコール及び/又は脂肪酸の過酸化物価が40meq/kg以下であることを特徴とする、上記1~4のいずれかに記載の本発明医療用皮膚外用剤。
(7)アルコール及び/又は脂肪酸の炭素数が16~22の範囲内である、上記1~6のいずれかに記載の本発明医療用皮膚外用剤。
(8)アルコール及び/又は脂肪酸の炭素数が18である、上記1~6のいずれかに記載の本発明医療用皮膚外用剤。
(9)アルコール及び/又は脂肪酸が不飽和の炭素結合を有するものである、上記1~6のいずれかに記載の本発明医療用皮膚外用剤。
(10)アルコール及び/又は脂肪酸が分岐鎖を有するものである、上記1~6のいずれかに記載の本発明医療用皮膚外用剤。
(11)ラウリルアルコール、ヘキシルデカノール、イソステアリルアルコール、オレイルアルコール、オクチルドデカノール、オレイン酸、イソステアリン酸及び/又はステアリン酸である、上記1~6のいずれかに記載の本発明医療用皮膚外用剤。
(12)アルコールの添加量が0.1~40重量%の範囲内である、上記1~11のいずれかに記載の本発明医療用皮膚外用剤。
(13)脂肪酸の添加量が0.1~40重量%の範囲内である、上記1~11のいずれかに記載の本発明医療用皮膚外用剤。
・炭素数12のアルコール:ラウリルアルコール
・炭素数13のアルコール:トリデシルアルコール
・炭素数14のアルコール:ミリスチルアルコール
・炭素数15のアルコール:ペンタデシルアルコール
・炭素数16のアルコール:セタノール(セチルアルコール、パルミチルアルコール)、ヘキシルデカノール、パルミトレイルアルコール
・炭素数17のアルコール:1-ヘプタデカノール
・炭素数18のアルコール:ステアリルアルコール、イソステアリルアルコール、オレイルアルコール、エライジルアルコール、リノレイルアルコール、エライドリノレイルアルコール、リノレニルアルコール、エライドリノレニルアルコール、リシノレイルアルコール
・炭素数19のアルコール:キミルアルコール(グリセリルモノセチルエーテル)、ノナデシルアルコール
・炭素数20のアルコール:オクチルドデカノール、アラキジルアルコール
・炭素数21のアルコール:バチルアルコール(グリセリルモノステアリルエーテル)、セラキルアルコール(モノオレイルグリセリルエ一テル)、ヘンエイコサノール
・炭素数22のアルコール:ベヘニルアルコール、エルシルアルコール
・炭素数24のアルコール:デシルテトラデカノール、リグノセリルアルコール
・炭素数26のアルコール:セリルアルコール
・炭素数27のアルコール:コレステロール(コレステリン)、1-ヘプタコサノール
・炭素数28のアルコール:モンタニルアルコール
・炭素数29のアルコール:シトステロール(シトステリン)、1-ノナコサノール
・炭素数30のアルコール:ミリシルアルコール
・炭素数32のアルコール:1-ドトリアコンタノール
・炭素数34のアルコール:ゲジルアルコール
また、例えば、ステアリルアルコールとセタノールを混合したセトステアリルアルコールのように、複数のアルコールを混合したアルコールも挙げられる。このようなアルコールとしては、例えば、フィトステロール(フィトステリン)、ラノリンアルコール又は水素添加ラノリンアルコールが挙げられる。
・炭素数12の脂肪酸:ラウリン酸
・炭素数14の脂肪酸:ミリスチン酸
・炭素数15の脂肪酸:ペンタデシル酸
・炭素数16の脂肪酸:パルミチン酸、パルミトレイン酸
・炭素数17の脂肪酸:マルガリン酸
・炭素数18の脂肪酸:ステアリン酸、イソステアリン酸、オレイン酸、リノール酸、バクセン酸、リノレン酸、エレオステアリン酸
・炭素数20の脂肪酸:アラキジン酸、8,11-エイコサジエン酸、ミード酸、アラキドン酸
・炭素数22の脂肪酸:ベヘン酸
・炭素数24の脂肪酸:リグノセリン酸、ネルボン酸
・炭素数25の脂肪酸:ペンタコサン酸
・炭素数26の脂肪酸:セロチン酸
・炭素数28の脂肪酸:モンタン酸
・炭素数30の脂肪酸:メリシン酸
なお、化合物Aの分解物は、以下の化学式で示された化合物(1-シクロプロピル-3-ヒドロキシ-8-メチル-7-(5-メチル-6-(メチルアミノ)ピリジン-3-イル)キノリン-4(1H)-オン)であった。
かかるpH調節剤は、緩衝能を有する化合物であれば特に限定されないが、例えば、水酸化カリウム、水酸化リチウム及び水酸化ナトリウムなどの金属水酸化物;モノエタノールアミン、モノイソプロパノールアミン、ジエタノールアミン、ジイソプロパノールアミン、トリエタノールアミン、トリイソプロパノールアミン及び2-アミノ-2-メチル-1,3-プロパンジオールなどのヒドロキシ低級アルキルアミン;炭酸水素ナトリウム、クエン酸ナトリウム、乳酸ナトリウム、リン酸水素二ナトリウム、酒石酸ナトリウムなどの弱酸の金属塩が挙げられ、これらを1種又は2種以上用いることができる。
さらに、pH調節剤の添加量は、本発明医療用皮膚外用剤のpHを9~13に調整することができれば特に限定されないが、0.1~20重量%の範囲内が適当であり、0.1~10重量%の範囲内が好ましく、0.1~5重量%の範囲内がより好ましい。
附属器関連感染症としては、例えば、毛包炎、毛瘡又は化膿性汗孔周囲炎を挙げることができる。
非附属器関連感染症としては、例えば、伝染性膿痂疹を挙げることができる。
附属器関連感染症としては、例えば、せつ、せつ腫症又はようを挙げることができる。
非附属器関連感染症としては、例えば、蜂巣炎、丹毒、リンパ管炎又はリンパ節炎を挙げることができる。
慢性膿皮症としては、例えば、感染性粉瘤、化膿性汗腺炎を挙げることができる。
皮膚二次感染症としては、例えば、皮膚潰瘍などの二次感染を挙げることができる。
医療用皮膚外用剤の調製
表1~3に示した処方に基づき、各成分を秤量した。化合物Aに水及びpH調節剤を加えて撹拌し、主薬相を得た。別に、水にpH調節剤を加えて撹拌し、pH調節相を得た。白色ワセリン、アルコール及び/又は脂肪酸を含む油相を70~80℃に加温して溶解させた。油相に主薬相及びpH調節相を加え、乳化機(プライミクス株式会社製)で撹拌し、実施例のクリーム剤を得た。
皮下脂肪を取り除いたヒト皮膚切片をフランツ垂直型透過セル(ハンソンリサーチ社製)に取り付け、1.77cm2当たり約20mgになるようクリーム3、13~17をそれぞれ塗布した後、レセプター液を灌流し、LC/MS/MS(液体クロマトグラフ(LC):株式会社島津製作所製、タンデム型質量分析計(MS/MS):株式会社エービー・サイエックス製)にて累積ヒト皮膚透過量を継時的に測定した。1製剤当たりに用いるヒト皮膚切片は6~8枚とした。結果を図1に示す。
表1~3に示した医療用皮膚外用剤中の分解物(1-シクロプロピル-3-ヒドロキシ-8-メチル-7-(5-メチル-6-(メチルアミノ)ピリジン-3-イル)キノリン-4(1H)-オン)の生成量を、高速液体クロマトグラフィーを用いて測定した。分解物の測定は、製剤を調製した直後に実施した。
Claims (13)
- 1-シクロプロピル-8-メチル-7-[5-メチル-6-(メチルアミノ)-3-ピリジル]-4-オキソ-1,4-ジヒドロ-3-キノリンカルボン酸及び/又はその医薬上許容される塩を有効成分として含有し、炭素数が12以上のアルコール及び/又は脂肪酸を含有する医療用皮膚外用剤。
- さらに、有効成分の安定性に優れた請求項1に記載の医療用皮膚外用剤。
- 当該有効成分の分解物の含有量が当該有効成分の0.5%以下であることを特徴とする、請求項1又は2に記載の医療用皮膚外用剤。
- 当該有効成分の分解物が1-シクロプロピル-3-ヒドロキシ-8-メチル-7-(5-メチル-6-(メチルアミノ)ピリジン-3-イル)キノリン-4(1H)-オンであることを特徴とする、請求項1~3のいずれか1項に記載の医療用皮膚外用剤。
- アルコール及び/又は脂肪酸の過酸化物価が120meq/kg以下であることを特徴とする、請求項1~4のいずれか1項に記載の医療用皮膚外用剤。
- アルコール及び/又は脂肪酸の過酸化物価が40meq/kg以下であることを特徴とする、請求項1~4のいずれか1項に記載の医療用皮膚外用剤。
- アルコール及び/又は脂肪酸の炭素数が16~22の範囲内である、請求項1~6のいずれか1項に記載の医療用皮膚外用剤。
- アルコール及び/又は脂肪酸の炭素数が18である、請求項1~6のいずれか1項に記載の医療用皮膚外用剤。
- アルコール及び/又は脂肪酸が不飽和の炭素結合を有するものである、請求項1~6のいずれか1項に記載の医療用皮膚外用剤。
- アルコール及び/又は脂肪酸が分岐鎖を有するものである、請求項1~6のいずれか1項に記載の医療用皮膚外用剤。
- ラウリルアルコール、ヘキシルデカノール、イソステアリルアルコール、オレイルアルコール、オクチルドデカノール、オレイン酸、イソステアリン酸及び/又はステアリン酸である、請求項1~6のいずれか1項に記載の医療用皮膚外用剤。
- アルコールの添加量が0.1~40重量%の範囲内である、請求項1~11のいずれか1項に記載の医療用皮膚外用剤。
- 脂肪酸の添加量が0.1~40重量%の範囲内である、請求項1~11のいずれか1項に記載の医療用皮膚外用剤。
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017562796A JP6504728B2 (ja) | 2016-12-01 | 2017-11-30 | 医療用皮膚外用剤 |
CA3042980A CA3042980A1 (en) | 2016-12-01 | 2017-11-30 | Medical skin external preparation |
MX2019005372A MX2019005372A (es) | 2016-12-01 | 2017-11-30 | Preparacion medica externa para la piel. |
SG11201903834XA SG11201903834XA (en) | 2016-12-01 | 2017-11-30 | Medical skin external preparation |
CN201780074246.5A CN110035755A (zh) | 2016-12-01 | 2017-11-30 | 医疗用皮肤外用剂 |
EP17876674.7A EP3549586A1 (en) | 2016-12-01 | 2017-11-30 | Medical skin external preparation |
KR1020197015092A KR20190093562A (ko) | 2016-12-01 | 2017-11-30 | 의료용 피부 외용제 |
US16/465,559 US11439634B2 (en) | 2016-12-01 | 2017-11-30 | Medical skin external preparation |
PH12019501206A PH12019501206A1 (en) | 2016-12-01 | 2019-05-30 | Medical skin external preparation |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016-234508 | 2016-12-01 | ||
JP2016234508 | 2016-12-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018101443A1 true WO2018101443A1 (ja) | 2018-06-07 |
Family
ID=62241709
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2017/043180 WO2018101443A1 (ja) | 2016-12-01 | 2017-11-30 | 医療用皮膚外用剤 |
Country Status (10)
Country | Link |
---|---|
US (1) | US11439634B2 (ja) |
EP (1) | EP3549586A1 (ja) |
JP (1) | JP6504728B2 (ja) |
KR (1) | KR20190093562A (ja) |
CN (1) | CN110035755A (ja) |
CA (1) | CA3042980A1 (ja) |
MX (1) | MX2019005372A (ja) |
PH (1) | PH12019501206A1 (ja) |
SG (1) | SG11201903834XA (ja) |
WO (1) | WO2018101443A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20200352840A1 (en) * | 2019-05-06 | 2020-11-12 | Spinart, LLC | Formulations and methods for preparing stable cosmetic compositions |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63287718A (ja) * | 1987-05-20 | 1988-11-24 | Shiseido Co Ltd | 液晶型外用基剤 |
WO1999051588A1 (fr) | 1998-04-06 | 1999-10-14 | Toyama Chemical Co., Ltd. | Derives d'acide quinolonecarboxylique ou sels de ceux-ci |
JP2002356426A (ja) * | 2001-03-26 | 2002-12-13 | Toyama Chem Co Ltd | ピリドンカルボン酸系化合物を含有する皮膚外用剤 |
JP2003012497A (ja) * | 2001-04-25 | 2003-01-15 | Eisai Co Ltd | 尿素含有外用組成物 |
WO2007015453A1 (ja) | 2005-08-01 | 2007-02-08 | Maruho Co., Ltd. | ピリドンカルボン酸誘導体を含有するローション剤 |
JP2012505867A (ja) * | 2008-10-17 | 2012-03-08 | フエルレル インターナショナル,ソシエダッド アノニマ | 局所用医薬組成物 |
JP2016515525A (ja) * | 2013-03-15 | 2016-05-30 | メディシス ファーマシューティカル コーポレイション | フルニソリドの局所用組成物および治療方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016129657A1 (ja) * | 2015-02-13 | 2016-08-18 | マルホ株式会社 | ピリドンカルボン酸系誘導体を含有する外用剤 |
-
2017
- 2017-11-30 EP EP17876674.7A patent/EP3549586A1/en not_active Withdrawn
- 2017-11-30 WO PCT/JP2017/043180 patent/WO2018101443A1/ja unknown
- 2017-11-30 MX MX2019005372A patent/MX2019005372A/es unknown
- 2017-11-30 KR KR1020197015092A patent/KR20190093562A/ko unknown
- 2017-11-30 JP JP2017562796A patent/JP6504728B2/ja active Active
- 2017-11-30 CA CA3042980A patent/CA3042980A1/en active Pending
- 2017-11-30 SG SG11201903834XA patent/SG11201903834XA/en unknown
- 2017-11-30 CN CN201780074246.5A patent/CN110035755A/zh active Pending
- 2017-11-30 US US16/465,559 patent/US11439634B2/en active Active
-
2019
- 2019-05-30 PH PH12019501206A patent/PH12019501206A1/en unknown
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63287718A (ja) * | 1987-05-20 | 1988-11-24 | Shiseido Co Ltd | 液晶型外用基剤 |
WO1999051588A1 (fr) | 1998-04-06 | 1999-10-14 | Toyama Chemical Co., Ltd. | Derives d'acide quinolonecarboxylique ou sels de ceux-ci |
JP2002356426A (ja) * | 2001-03-26 | 2002-12-13 | Toyama Chem Co Ltd | ピリドンカルボン酸系化合物を含有する皮膚外用剤 |
JP2003012497A (ja) * | 2001-04-25 | 2003-01-15 | Eisai Co Ltd | 尿素含有外用組成物 |
WO2007015453A1 (ja) | 2005-08-01 | 2007-02-08 | Maruho Co., Ltd. | ピリドンカルボン酸誘導体を含有するローション剤 |
JP2012505867A (ja) * | 2008-10-17 | 2012-03-08 | フエルレル インターナショナル,ソシエダッド アノニマ | 局所用医薬組成物 |
JP2016515525A (ja) * | 2013-03-15 | 2016-05-30 | メディシス ファーマシューティカル コーポレイション | フルニソリドの局所用組成物および治療方法 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20200352840A1 (en) * | 2019-05-06 | 2020-11-12 | Spinart, LLC | Formulations and methods for preparing stable cosmetic compositions |
Also Published As
Publication number | Publication date |
---|---|
EP3549586A1 (en) | 2019-10-09 |
US20190282562A1 (en) | 2019-09-19 |
KR20190093562A (ko) | 2019-08-09 |
CA3042980A1 (en) | 2018-06-07 |
JPWO2018101443A1 (ja) | 2019-01-31 |
MX2019005372A (es) | 2019-07-10 |
PH12019501206A1 (en) | 2019-12-11 |
JP6504728B2 (ja) | 2019-04-24 |
US11439634B2 (en) | 2022-09-13 |
CN110035755A (zh) | 2019-07-19 |
SG11201903834XA (en) | 2019-05-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7242222B2 (ja) | ロフルミラストの結晶成長の妨害 | |
US11612573B2 (en) | Topical pharmaceutical compositions | |
JP7402301B2 (ja) | 水混和性の薬学的に許容可能な溶媒の水性ブレンド中のロフルミラストの医薬組成物 | |
WO2011080148A2 (en) | An aqueous intravenous nanosuspension with reduced adverse effects | |
FR2890559A1 (fr) | Mousses dermatologiques a base de metronidazole et emulsions pour la preparation | |
NL8303412A (nl) | Nieuwe topicaal toepasbare farmaceutische samenstellingen. | |
US20240000760A1 (en) | Roflumilast Formulations with an Improved Pharmacokinetic Profile | |
US20230126208A1 (en) | Topical pharmaceutical compositions | |
TWI245640B (en) | Topical pharmaceutical compositions for treatment of skin disorders | |
WO2018101443A1 (ja) | 医療用皮膚外用剤 | |
JP5743241B2 (ja) | 外用医薬組成物 | |
JP4463621B2 (ja) | 抗炎症作用を有する皮膚外用剤 | |
JP2006321725A (ja) | 乳化剤形の皮膚外用剤 | |
KR102669247B1 (ko) | 국소 제약 조성물 | |
WO2022169615A1 (en) | Roflumilast formulations with an improved pharmacokinetic profile | |
WO2024058848A1 (en) | Pharmaceutical compositions of roflumilast and solvents capable of dissolving high amounts of the drug | |
WO2020021670A1 (ja) | 液状外用剤 | |
UA107968C2 (uk) | Фармацевтичні композиції для місцевого застосування | |
TR201620366A1 (tr) | Topi̇kal formülasyonlar |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref document number: 2017562796 Country of ref document: JP Kind code of ref document: A |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17876674 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3042980 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 20197015092 Country of ref document: KR Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2017876674 Country of ref document: EP Effective date: 20190701 |